

Nuclear Meds Set Off Sensors Up to 3 Months

BY KATE JOHNSON
Montreal Bureau

CHICAGO — Patients given radiopharmaceuticals for diagnostic or therapeutic nuclear medicine procedures can trigger radiation detectors up to 3 months after the procedure, Lionel S. Zuckier, M.D., said at the annual meeting of the Radiological Society of North America.

These patients should be given appropriate documentation, said Dr. Zuckier, director of nuclear medicine and positron emission tomography at the University Hospital, Newark, N.J.

"Many patients have been picked up and detained ... and now we expect it to be a more common occurrence with the increasing number of extremely sensitive portable radiation detectors being distributed to local, state, and federal emergency responders," he said.

Physicians should counsel patients about informed consent and advise them to carry letters of clarification to make any interactions with law enforcement personnel easier, he said.

Carrying such documentation is consistent with guidelines issued by both the Society of Nuclear Medicine and the U.S. Nuclear Regulatory Commission.

"This letter should include a contact name and number so that the information can be verified at any time. Our department has a 24-hour number that can be called," said Dr. Zuckier, also a professor of radiology at the University of Medicine and Dentistry of New Jersey, Newark.

According to Dr. Zuckier, there were 18 million nuclear medicine procedures performed in 2002 in the United States.

With 10,000 portable Homeland Security radiation detectors in use, there is great potential for patients to be inconvenienced at airports or other security points.

His study, which he presented at the meeting, examined the strength of five radiation detection devices currently in use by the U.S. Homeland Security Department.

Therapeutic radiopharmaceuticals, such as iodine, used in the treatment of thyroid disorders, can be detected in the body and therefore have the potential to trigger radiation detectors up to 3 months after the procedure.

Patients who undergo cardiac exams with thallium can trigger alarms for up to 30 days, and patients who undergo bone and thyroid scans have detectable radiation levels for up to 3 days.

Patients undergoing PET scans with ¹⁸fluorodeoxyglucose are at risk for triggering radiation detectors for less than 24 hours post procedure, he said.

"These detectors are extremely sensitive and can pick up dose rates as small as 1 or 2 microrads per hour. Our study suggests guidelines as to how long [a patient's] documentation should be retained," Dr. Zuckier said. ■

Clears constipation quickly

ACUTE & CHRONIC CONSTIPATION

Gentle relief in as little as 24 hours, and for as long as needed

- ✱ Works quickly, usually in 24 to 48 hours
- ✱ Gentle, osmotic effect
- ✱ Indicated for acute and chronic constipation and has no restrictions on length of use*
 - *MiraLax™ is indicated for occasional constipation and should be used for 2 weeks or less or as directed by a physician**
- ✱ Taste-free, grit-free crystal formulation
- ✱ Dissolves quickly in only 4 ounces of water
- ✱ Available in convenient 10 g and 20 g single-dose packets
- ✱ Rx only

Kristalose®
(lactulose) For Oral Solution
Rapid, gentle relief

For samples call 888-5-BERTEK

KRI-LIT-002T

Contraindicated in patients who require a low galactose diet. Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics.

Please see brief summary of Prescribing Information.

*Elderly, debilitated patients who receive lactulose for more than 6 months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.

*MiraLax is a trademark of Brintree Laboratories, Inc.

Reference: 1. MiraLax [prescribing information]. Brintree Laboratories, Inc., 2001.



A different kind of lactulose

- ✱ No syrupy-sweet taste or stickiness

Brief Summary: Before prescribing, please see complete prescribing information. **INDICATIONS AND USAGE:** For the treatment of constipation. **CONTRAINDICATIONS:** Since KRISTALOSE® (LACTULOSE) For Oral Solution contains galactose (less than 0.3 g/10 g as a total sum with lactose), it is contraindicated in patients who require a low galactose diet. **WARNINGS:** A theoretical hazard may exist for patients being treated with lactulose who may be required to undergo electrocautery procedures during proctoscopy or colonoscopy. Accumulation of H₂ gas in significant concentration in the presence of an electrical spark may result in an explosive reaction. Although this complication has not been reported with lactulose, patients on lactulose therapy undergoing such procedures should have a thorough bowel cleansing with a non-fermentable solution. Insufflation of CO₂ as an additional safeguard may be pursued but is considered to be a redundant measure. **PRECAUTIONS:** General: Since KRISTALOSE® (LACTULOSE) For Oral Solution contains galactose and lactose (less than 0.3 g/10 g as a total sum), it should be used with caution in diabetics. **Information for Patients:** In the event that an unusual diarrheal condition occurs, contact your physician. **Laboratory Tests:** Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. **Drug Interactions:** Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose. **Carcinogenesis, Mutagenesis, Impairment of Fertility:** There are no known human data on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility. There are no known animal data on long-term potential for mutagenicity. Administration of lactulose syrup in the diet of mice for 18 months in concentrations of 3 and 10 percent (w/v) did not produce any evidence of carcinogenicity. In studies in mice, rats, and rabbits, doses of lactulose syrup up to 6 or 12 mL/kg/day produced no deleterious effects in breeding, conception, or parturition. **Pregnancy-Teratogenic Effects: Pregnancy Category B:** Reproduction studies have been performed in mice, rats, and rabbits at doses up to 3 or 6 times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. **Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lactulose is administered to a nursing woman. **Pediatric Use:** Safety and effectiveness in pediatric patients have not been established. **ADVERSE REACTIONS:** Precise frequency data are not available. Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia. Nausea and vomiting have been reported. **OVERDOSAGE: Signs and Symptoms:** There have been no reports of accidental overdosage. In the event of overdosage, it is expected that diarrhea and abdominal cramps would be the major symptoms. Medication should be terminated. **Oral LD₅₀:** The acute oral LD₅₀ of the drug is 48.8 mL/kg in mice and greater than 30 mL/kg in rats. **Dialysis:** Dialysis data are not available for lactulose. Its molecular similarity to sucrose, however, would suggest that it should be dialyzable. Rx only. **STORAGE:** Store at room temperature, 15°-30°C (59°-86°F). Distributed by Bertek Pharmaceuticals Inc. Sugar Land, TX 77478